{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:59:00Z","timestamp":1791107940596,"version":"4.1.0"},"reference-count":424,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicinal Research Reviews"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiogenesis, the generation of new capillaries through a process of pre\u2010existing microvessel sprouting, is under stringent control and normally occurs only during embryonic and post\u2010embryonic development, reproductive cycle, and wound repair. However, in many pathological conditions (solid tumor progression, metastasis, diabetic retinopathy, hemangioma, arthritis, psoriasis and atherosclerosis among others), the disease appears to be associated with persistent upregulated angiogenesis. The development of specific anti\u2010angiogenic agents arises as an attractive therapeutic approach for the treatment of cancer and other angiogenesis\u2010dependent diseases. The formation of new blood vessels is a complex multi\u2010step process. Endothelial cells resting in the parent vessels are activated by an angiogenic signal and stimulated to synthesize and release degradative enzymes allowing endothelial cells to migrate, proliferate and finally differentiate to give rise to capillary tubules. Any of these steps may be a potential target for pharmacological intervention. In spite of the disappointing results obtained initially in clinical trials with anti\u2010angiogenic drugs, recent reports with positive results in phases II and III trials encourage expectations in their therapeutic potential. This review discusses the current approaches for the discovery of new compounds that inhibit angiogenesis, with emphasis on the clinical developmental status of anti\u2010angiogenic drugs. \u00a9 2006 Wiley Periodicals, Inc. Med Res Rev, 26, No. 4, 483\u2013530, 2006<\/jats:p>","DOI":"10.1002\/med.20059","type":"journal-article","created":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T22:52:18Z","timestamp":1146523938000},"page":"483-530","source":"Crossref","is-referenced-by-count":135,"title":["Anti\u2010angiogenic drugs: from bench to clinical trials"],"prefix":"10.1002","volume":"26","author":[{"given":"Ana R.","family":"Quesada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Mu\u00f1oz\u2010Ch\u00e1puli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,5]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958010-00003"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/36978"},{"key":"e_1_2_1_4_2","first-page":"5117","article-title":"Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR\/Flk\u20101) activity by a monoclonal anti\u2010VEGF antibody blocks tumor growth in mice","volume":"60","author":"Brekken RA","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.671.65.3"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/362841a0"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-suppl_1-11"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00115-9"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.066"},{"key":"e_1_2_1_10_2","article-title":"Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first\u2010line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5\u2010FU\u2010LV) as a first\u2010line therapy in subjects with metastatic CRC","volume":"22","author":"Hurwitz H","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_1_12_2","article-title":"High\u2010dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200","author":"Mitchell EP","year":"2005","journal-title":"Gastrointestinal Cancers Symposium"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.2"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-3-191"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021491"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/jco.2004.22.90140.4502","article-title":"Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)","volume":"22","author":"Hainsworth J","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1200\/jco.2005.23.16_suppl.4540","article-title":"Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial","volume":"23","author":"Spigel DR","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0605"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"e_1_2_1_20_2","article-title":"E2100: A randomized phase III trial of paclitaxel plus bevacizumab as first\u2010line therapy for locally recurrent or metastatic breast cancer","author":"Miller KD","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.477"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.lba4"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012245307884"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119740"},{"key":"e_1_2_1_26_2","first-page":"49","article-title":"Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor","volume":"9","author":"Lin P","year":"1998","journal-title":"Cell Growth Differ"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-200208000-00001"},{"key":"e_1_2_1_28_2","first-page":"2169","article-title":"Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ","volume":"60","author":"Takayama K","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700478"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172398299"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172398399"},{"key":"e_1_2_1_32_2","first-page":"5721","article-title":"Vascular endothelial growth factor\u2010trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model","volume":"9","author":"Byrne AT","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1432908100"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10246"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.3029"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00529-3"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.437"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70104-6"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199705000-00011"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.133.12.1567"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2370"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1311"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.052"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10088"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.070"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.116"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.185"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1103-3"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.952"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1089\/107999004772719891"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.907"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240290310"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.457"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00152a044"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1996.0142"},{"key":"e_1_2_1_56_2","first-page":"2654","article-title":"Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase\u2010type plasminogen activator","volume":"54","author":"Takano S","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050885"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.272"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015666024386"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01240125"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869709109226"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015666024386"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11867"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.172"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90020-5"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2000.5920"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1159\/000139538"},{"key":"e_1_2_1_68_2","first-page":"3955","article-title":"Suradista NSC 651016 inhibits the angiogenic activity of CXCL12\u2010stromal cell\u2010derived factor 1alpha","volume":"8","author":"Schneider GP","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_69_2","first-page":"3928","article-title":"PNU\u2010145156E, a novel angiogenesis inhibitor, in patients with solid tumors: A phase I and pharmacokinetic study","volume":"7","author":"Groen HJ","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_70_2","first-page":"2143","article-title":"Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo","volume":"13","author":"Nguyen NM","year":"1993","journal-title":"Anticancer Res"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010797"},{"key":"e_1_2_1_72_2","first-page":"2347","article-title":"Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer","volume":"3","author":"Marshall JL","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089169608200412"},{"key":"e_1_2_1_74_2","first-page":"S21","article-title":"The role of pentosan polysulfate in treatment approaches for interstitial cystitis","volume":"4","author":"Teichman JMH","year":"2002","journal-title":"Rev Urol"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015219716583"},{"key":"e_1_2_1_76_2","first-page":"183","article-title":"Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells","volume":"59","author":"Arora N","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122157899"},{"key":"e_1_2_1_78_2","first-page":"942","article-title":"Increased Sophistication of Immunotoxins","volume":"8","author":"Frankel AE","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006314501634"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11631"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/27.13.2569"},{"key":"e_1_2_1_82_2","volume-title":"Intracellular ribozyme applications: Principles and protocols","author":"Parry TJ","year":"1999"},{"key":"e_1_2_1_83_2","first-page":"2094","article-title":"Antitumor and antimetastatic activity of ribozymes targeting the mRNAof vascular growth factor receptors","volume":"6","author":"Pavco PA","year":"2000","journal-title":"Clinical Cancer Res"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.1.2000.10.153"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1089\/oli.1.1999.9.271"},{"key":"e_1_2_1_86_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127000004001217"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-001-0014-7"},{"key":"e_1_2_1_88_2","first-page":"256","article-title":"Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR\u20101: Results of a Phase II trial of ANGIOZYME, a ribozyme targeting the pre\u2010mRNA of VEGFR\u20101, in combination with chemotherapy","volume":"22","author":"Venook A","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi981931e"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00056-1"},{"key":"e_1_2_1_91_2","first-page":"5209","article-title":"Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors","volume":"59","author":"Prewett M","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_92_2","first-page":"6624","article-title":"Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor\u20102","volume":"61","author":"Kunkel P","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(01)01759-7"},{"key":"e_1_2_1_94_2","first-page":"3209","article-title":"Inhibition of vascular endothelial growth factor\u2010induced receptor activation with anti\u2010kinase insert domain\u2010containing receptor single\u2010chain antibodies from a phage display library","volume":"58","author":"Zhu Z","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_95_2","first-page":"1323","article-title":"A phase I study of anti\u2010kinase insert domain\u2010containing receptor antibody, IMC\u20101C11, in patients with liver metastases from colorectal carcinoma","volume":"9","author":"Posey JA","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307742200"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402831"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568009023333881"},{"key":"e_1_2_1_99_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1535-7163.MCT-04-0261","article-title":"A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3","volume":"4","author":"Jimenez X","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_1_100_2","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk\u20101\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong TA","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_101_2","first-page":"5412","article-title":"Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis","volume":"59","author":"Shaheen RM","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_102_2","first-page":"5536","article-title":"Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas","volume":"59","author":"Angelov L","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.09.063"},{"key":"e_1_2_1_104_2","first-page":"4848","article-title":"The angiogenesis inhibitor SU5416 has long\u2010lasting effects on vascular endothelial growth factor receptor phosphorylation and function","volume":"6","author":"Mendel DB","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_105_2","first-page":"29","article-title":"Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti\u2010angiogenesis agent","volume":"15","author":"Mendel DB","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"e_1_2_1_106_2","first-page":"1312","article-title":"Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416","volume":"14","author":"Via LE","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_1_107_2","first-page":"116b","article-title":"SU5416 in advanced colorectal cancer (CRC): A University of Chicago Phase II Consortium Study","volume":"20","author":"Eng C","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_108_2","first-page":"288a","article-title":"A phase II study with SU5416 in patients with C\u2010Kit positive AML","volume":"20","author":"Fiedler WM","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_109_2","first-page":"360a","article-title":"Phase II study of the anti\u2010angiogenic Flk\u20101 tyrosine kinase inhibitor SU5416 in melanoma: Initial results","volume":"20","author":"Gajewski TF","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_110_2","first-page":"341a","article-title":"SU5416 in malignant mesothelioma: A University of Chicago phase II consortium study","volume":"20","author":"Kindler HL","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_111_2","first-page":"98a","article-title":"A phase I and pharmacokinetic study of single oral administration of SU5416 in patients with advanced solid tumors","volume":"20","author":"Salzberg M","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3851"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3023"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000030186.66672.36"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0157"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3023"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0221-3"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-2998"},{"key":"e_1_2_1_119_2","first-page":"4772","article-title":"SU5416 Plus interferon {alpha} in advanced renal cell carcinoma: A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition","volume":"9","author":"Lara PN","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0157"},{"key":"e_1_2_1_121_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0766"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0404"},{"key":"e_1_2_1_123_2","first-page":"4152","article-title":"SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors","volume":"60","author":"Laird AD","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0700com"},{"key":"e_1_2_1_125_2","first-page":"1464","article-title":"Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms","volume":"61","author":"Shaheen RM","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_126_2","first-page":"3476","article-title":"The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically","volume":"9","author":"Garofalo A","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_127_2","first-page":"1142","article-title":"Su\u20106668","volume":"2","author":"Fabbro D","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_1_128_2","first-page":"97a","article-title":"Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies","volume":"20","author":"Rosen LS","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_129_2","first-page":"28b","article-title":"Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers","volume":"21","author":"Britten CD","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.3001"},{"key":"e_1_2_1_131_2","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet\u2010derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel DB","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2307"},{"key":"e_1_2_1_133_2","first-page":"1011","article-title":"Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \u201cstandard of care\u201d therapeutic agents for the treatment of breast cancer","volume":"2","author":"Abrams TJ","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:CLIN.0000006873.65590.68"},{"key":"e_1_2_1_135_2","first-page":"4009","article-title":"SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models","volume":"63","author":"Schueneman AJ","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_1_136_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3381"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1846"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.99.322"},{"key":"e_1_2_1_139_2","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/jco.2005.23.16_suppl.4508","article-title":"Phase 2 trials of SU11248 show antitumor activity in second\u2010line therapy for patients with metastatic renal cell carcinoma (RCC)","volume":"23","author":"Motzer RJ","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_140_2","doi-asserted-by":"crossref","first-page":"8167","DOI":"10.1200\/jco.2005.23.16_suppl.8167","article-title":"Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma","volume":"23","author":"Beaumont J","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_141_2","article-title":"Clinical activity and tolerability of the multi\u2010targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate","volume":"22","author":"Demetri GD","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.9011"},{"key":"e_1_2_1_143_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.4000"},{"key":"e_1_2_1_144_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/jco.2005.23.16_suppl.563","article-title":"Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)","volume":"23","author":"Miller KD","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_145_2","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/jco.2005.23.16_suppl.4008","article-title":"A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)","volume":"23","author":"Kulke M","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_146_2","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor\u2010induced responses and tumor growth after oral administration","volume":"60","author":"Wood JM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_147_2","doi-asserted-by":"publisher","DOI":"10.1089\/108497801753354267"},{"key":"e_1_2_1_148_2","first-page":"1996","article-title":"Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer","volume":"62","author":"Baker CH","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_149_2","first-page":"100a","article-title":"A phase\u20101 dose\u2010escalating and pharmacokinetic (PK) study of the VEGF\u2010receptor\u2010inhibitor PTK787\/ZK222584 (PTK\/ZK) in patients with liver metastasis of advanced cancer","volume":"20","author":"Drevs J","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_150_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.092"},{"key":"e_1_2_1_151_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/jco.2004.22.90140.3556","article-title":"Expanded phase I\/II study of PTK787\/ZK 222584 (PTK\/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX\u20104 as first\u2010line treatment for patients with metastatic colorectal cancer","volume":"22","author":"Steward WP","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_152_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.lba3"},{"key":"e_1_2_1_153_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/jco.2004.22.90140.1513","article-title":"A phase I\/II trial of PTK787\/ZK 222584 (PTK\/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM)","volume":"22","author":"Reardon D","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_154_2","first-page":"970","article-title":"ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad\u2010spectrum antitumor efficacy","volume":"60","author":"Wedge SR","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_155_2","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge SR","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_156_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1147"},{"key":"e_1_2_1_157_2","first-page":"1546","article-title":"Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase","volume":"9","author":"Ciardiello F","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_158_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03187.x"},{"key":"e_1_2_1_159_2","article-title":"A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors","volume":"22","author":"Minami H","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_160_2","article-title":"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors","volume":"22","author":"Hurwitz H","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_161_2","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/jco.2005.23.16_suppl.3023","article-title":"A randomized, placebo\u2010controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC","volume":"23","author":"Heymach JV","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.7102"},{"key":"e_1_2_1_163_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023393026"},{"key":"e_1_2_1_164_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0080219"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_1_166_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP40580"},{"key":"e_1_2_1_167_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP42650"},{"key":"e_1_2_1_168_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602584"},{"key":"e_1_2_1_169_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.3037"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.126"},{"key":"e_1_2_1_171_2","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/jco.2004.22.90140.4501","article-title":"Preliminary antitumor activity of BAY 43\u20109006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)","volume":"22","author":"Ratain MJ","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_172_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.4544"},{"key":"e_1_2_1_173_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.lba4510"},{"key":"e_1_2_1_174_2","first-page":"2958","article-title":"A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello F","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_175_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200111000-00014"},{"key":"e_1_2_1_176_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208625"},{"key":"e_1_2_1_177_2","first-page":"252","article-title":"Cetuximab (C225) alone or in combination with irinotecan (CPT\u201011) in patients with epidermal growth factor receptor (EGFR)\u2010positive, irinotecan\u2010refractory metastatic colorectal cancer","volume":"22","author":"Cunningham D","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_178_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.147"},{"key":"e_1_2_1_179_2","first-page":"389","article-title":"Phase II study of anti\u2010epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC)","volume":"19","author":"Gunnett K","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_180_2","first-page":"4","article-title":"Continued response following treatment with IMC\u2010225, an EGFr MoAb, combined with RT in advanced head and neck malignancies","volume":"19","author":"Bonner JA","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_181_2","first-page":"224","article-title":"Efficacy and safety of the anti\u2010epidermal growth factor receptor antibody (EGFR) IMC\u2010C225 in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy","volume":"21","author":"Hong WK","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_182_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/jco.2004.22.90140.7010","article-title":"Results of a phase III trial of erlotinib (OSI\u2010774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non\u2010small cell lung cancer (NSCLC)","volume":"22","author":"Gatzemeier U","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_183_2","first-page":"264","article-title":"Cetuximab (C225) in combination with bi\u2010weekly irinotecan (CPT\u201011), infusional 5\u2010fluorouracil (5\u2010FU), and folinic acid (FA) in patients with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results","volume":"22","author":"Van Laethem J\u2010L","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_184_2","first-page":"130","article-title":"Phase II study of anti\u2010epidermal growth factor receptor (EGFR) antibody cetuximab (IMC\u2010C225) in combination with gemcitabine in patients with advanced pancreatic cancer","volume":"21","author":"Abbruzzese JL","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_185_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.5507"},{"key":"e_1_2_1_186_2","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/jco.2005.23.16_suppl.3574","article-title":"Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial","volume":"23","author":"Polikoff J","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_187_2","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1200\/jco.2005.23.16_suppl.3580","article-title":"Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC)","volume":"23","author":"Sobrero A","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_188_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.7036"},{"key":"e_1_2_1_189_2","doi-asserted-by":"crossref","first-page":"7135","DOI":"10.1200\/jco.2005.23.16_suppl.7135","article-title":"A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA\/B non\u2010small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 Trial","volume":"23","author":"Werner\u2010Wasik M","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_190_2","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/jco.2005.23.16_suppl.5047","article-title":"A phase II study of cetuximab\/paclitaxel\/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer","volume":"23","author":"Aghajanian C","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_191_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568011043482106"},{"key":"e_1_2_1_192_2","first-page":"629","article-title":"Disease\u2010related symptoms in advanced non\u2010small cell lung cancer (NSCLC) as measured by the Lung Cancer Subscale (LCS) of the FACT\u2010L questionnaire: Clinically meaningful improvements with gefitinib (IRESSA, ZD1839)","volume":"22","author":"Cella D","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_193_2","first-page":"265","article-title":"A II study of gefitinib (ZD1839, Iressa\u2122) combination with Folfox\u20104 (IFOX) in patients with unresectable or metastatic colorectal cancer","volume":"22","author":"Cho CD","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_194_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601476"},{"key":"e_1_2_1_195_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.051"},{"key":"e_1_2_1_196_2","article-title":"Phase I\u2010II study of ZD\u20101839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy","volume":"22","author":"Lieberman FS","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_197_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2004.00543.x"},{"key":"e_1_2_1_198_2","article-title":"Phase II trial of ZD1839 (Iressa) for patients with first relapse glioblastoma","volume":"22","author":"Peery TS","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_199_2","article-title":"Gefitinib (\u2018Iressa\u2019, ZD1839) is active in acquired tamoxifen (TAM)\u2010resistant oestrogen receptor (ER)\u2010positive and ER\u2010negative breast cancer: Results from a Phase II study","volume":"22","author":"Robertson JFR","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.12.014"},{"key":"e_1_2_1_201_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.110"},{"key":"e_1_2_1_202_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.158"},{"key":"e_1_2_1_203_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_2_1_204_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"e_1_2_1_205_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.799"},{"key":"e_1_2_1_206_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.7022"},{"key":"e_1_2_1_207_2","article-title":"A Phase III double blind trial of gemcitabine \u00b1 erlotinib in locally advanced\/metastatic pancreatic carcinoma","author":"Moore MJ","year":"2005","journal-title":"ASCO Gastrointest Cancers Symp"},{"key":"e_1_2_1_208_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.1"},{"key":"e_1_2_1_209_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-0081-0_19"},{"key":"e_1_2_1_210_2","first-page":"17","article-title":"Clinical experience with the HER1\/EGFR tyrosine kinase inhibitor erlotinib","volume":"11","author":"Sandler A","year":"2003","journal-title":"Oncology"},{"key":"e_1_2_1_211_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.075"},{"key":"e_1_2_1_212_2","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1200\/jco.2005.23.16_suppl.5546","article-title":"Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic\/recurrent head and neck squamous cell carcinoma (HNSCC)","volume":"23","author":"Kim ES","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_213_2","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1200\/jco.2005.23.16_suppl.7100","article-title":"Phase II pharmacodynamic trial of erlotinib in advanced non\u2010small cell lung cancer (NSCLC) patients previously treated with platinum\u2010based chemotherapy: preliminary results","volume":"23","author":"Felip E","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_214_2","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1200\/jco.2005.23.16_suppl.7073","article-title":"A phase II study of erlotinib as first\u2010line treatment of advanced non\u2010small cell lung cancer","volume":"23","author":"Giaccone G","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_215_2","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1200\/jco.2005.23.16_suppl.7148","article-title":"Phase II study of the EGFR tyrosine kinase erlotinib in patients 70 years of age with previously untreated advanced non\u2010small cell lung carcinoma","volume":"23","author":"Jackman D","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_216_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.1567"},{"key":"e_1_2_1_217_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.1507"},{"key":"e_1_2_1_218_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/jco.2005.23.16_suppl.644","article-title":"N0234: Phase II study of erlotinib (OSI\u2010774) plus gemcitabine as first\u2010or second\u2010line therapy for metastatic breast cancer (MBC)","volume":"23","author":"Graham DL","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_219_2","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1200\/jco.2005.23.16_suppl.4540","article-title":"Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial","volume":"23","author":"Spigel DR","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_220_2","first-page":"3175","article-title":"Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human HT\u201029 colon carcinoma and human CaKi1 renal cell carcinoma xenografts","volume":"21","author":"Teicher BA","year":"2001","journal-title":"Anticancer Res"},{"key":"e_1_2_1_221_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100372"},{"key":"e_1_2_1_222_2","first-page":"185","article-title":"Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts","volume":"15","author":"Teicher BA","year":"2001","journal-title":"In Vivo"},{"key":"e_1_2_1_223_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-001-0386-2"},{"key":"e_1_2_1_224_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016297611825"},{"key":"e_1_2_1_225_2","article-title":"Phase 1 study of LY317615, a protein kinase C inhibitor (abstract 326)","author":"Herbst RS","year":"2002","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"e_1_2_1_226_2","doi-asserted-by":"publisher","DOI":"10.1038\/348555a0"},{"key":"e_1_2_1_227_2","first-page":"3457","article-title":"A re\u2010evaluation of fumagillin selectivity towards endothelial cells","volume":"21","author":"Rodriguez\u2010Nieto S","year":"2001","journal-title":"Anticancer Res"},{"key":"e_1_2_1_228_2","first-page":"3407","article-title":"A fumagillin derivative angiogenesis inhibitor, AGM\u20101470, inhibits activation of cyclin\u2010dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells","volume":"54","author":"Abe J","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_1_229_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(97)90198-8"},{"key":"e_1_2_1_230_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5415.808"},{"key":"e_1_2_1_231_2","first-page":"971","article-title":"Therapeutic synergy of TNP\u2010470 and Ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenographs","volume":"6","author":"Lund EL","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_232_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1002"},{"key":"e_1_2_1_233_2","first-page":"1501","article-title":"A phase I study of TNP\u2010470 administered to patients with advanced squamous cell cancer of the cervix","volume":"3","author":"Kudelka AP","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_234_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1444"},{"key":"e_1_2_1_235_2","first-page":"1989","article-title":"A phase I and pharmacokinetic study of TNP\u2010470 administered weekly to patients with advanced cancer","volume":"5","author":"Bhargava P","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_236_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2541"},{"key":"e_1_2_1_237_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.006"},{"key":"e_1_2_1_238_2","first-page":"2784","article-title":"Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature","volume":"58","author":"Sills AK","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_239_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1999.276.1.C136"},{"key":"e_1_2_1_240_2","first-page":"3912","article-title":"A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers","volume":"7","author":"Bhargava P","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_241_2","first-page":"4108","article-title":"A phase I\/IIA trial of continuous five\u2010day infusion of squalamine lactate (MSI\u20101256F) plus carboplatin and paclitaxel in patients with advanced non\u2010small cell lung cancer","volume":"9","author":"Herbst RS","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_242_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-128"},{"key":"e_1_2_1_243_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi113"},{"key":"e_1_2_1_244_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199707150-00008"},{"key":"e_1_2_1_245_2","first-page":"295","article-title":"Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic","volume":"3","author":"Huang S","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_1_246_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200202000-00010"},{"key":"e_1_2_1_247_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022171"},{"key":"e_1_2_1_248_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500180102"},{"key":"e_1_2_1_249_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90200-3"},{"key":"e_1_2_1_250_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"e_1_2_1_251_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81926-1"},{"key":"e_1_2_1_252_2","first-page":"4887","article-title":"Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin","volume":"56","author":"Gately S","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_1_253_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009050309715"},{"key":"e_1_2_1_254_2","doi-asserted-by":"publisher","DOI":"10.2741\/1602"},{"key":"e_1_2_1_255_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.20.1520"},{"key":"e_1_2_1_256_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.061"},{"key":"e_1_2_1_257_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.120"},{"key":"e_1_2_1_258_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.082"},{"key":"e_1_2_1_259_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.7138"},{"key":"e_1_2_1_260_2","first-page":"3","article-title":"Recombinant human angiostatin (rhA): A Phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD)","volume":"20","author":"De Moraes ED","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_261_2","first-page":"4025","article-title":"Recombinant human angiostatin by twice\u2010daily subcutaneous injection in advanced cancer: A pharmokinetic and long\u2010term safety study","volume":"9","author":"Beerepoot LV","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_262_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37263"},{"key":"e_1_2_1_263_2","first-page":"7669","article-title":"Continuous administration of endostatin by intraperitoneally implanted osmoticpump improves the efficacy and potency of therapy in a mouse xenograft tumor model","volume":"61","author":"Kisker O","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_264_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700716"},{"key":"e_1_2_1_265_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.10.008"},{"key":"e_1_2_1_266_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1067100"},{"key":"e_1_2_1_267_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-95"},{"key":"e_1_2_1_268_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc884"},{"key":"e_1_2_1_269_2","first-page":"513","article-title":"Phase I study of intrapleural batimastat (BB\u201094), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions","volume":"5","author":"Macaulay VM","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_270_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.12.2913"},{"key":"e_1_2_1_271_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3447"},{"key":"e_1_2_1_272_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.108"},{"key":"e_1_2_1_273_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.054"},{"key":"e_1_2_1_274_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07689.x"},{"key":"e_1_2_1_275_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-0160"},{"key":"e_1_2_1_276_2","article-title":"Phase I study of the matrix metalloproteinase inhibitor AG340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors","volume":"18","author":"D'Olimpio J","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_277_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.9.2159"},{"key":"e_1_2_1_278_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.31528"},{"key":"e_1_2_1_279_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.170"},{"key":"e_1_2_1_280_2","first-page":"307a","article-title":"Phase III study of the matrix metalloproteinases (MMP) inhibitor prinomastat in patients having advanced non\u2010small cell lung cancer","volume":"20","author":"Smylie M","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_281_2","first-page":"296a","article-title":"Phase III study of the matrix metalloprotease inhibitor prinomastat in combination with gemcitibine and cisplatin in non\u2010small cell lung cancer","volume":"21","author":"Bissett D","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_282_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1160\/TH03-01-0041","article-title":"Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy","volume":"90","author":"Behrendt CE","year":"2003","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_283_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0071"},{"key":"e_1_2_1_284_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055636"},{"key":"e_1_2_1_285_2","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.24.2.86.8159"},{"key":"e_1_2_1_286_2","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.24.1.33.5429"},{"key":"e_1_2_1_287_2","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.24.1.33.5429"},{"key":"e_1_2_1_288_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.178"},{"key":"e_1_2_1_289_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100330"},{"key":"e_1_2_1_290_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02574483"},{"key":"e_1_2_1_291_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100330"},{"key":"e_1_2_1_292_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00149-0"},{"key":"e_1_2_1_293_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.9.2167"},{"key":"e_1_2_1_294_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601594"},{"key":"e_1_2_1_295_2","first-page":"8480","article-title":"Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS\u2010275291","volume":"61","author":"Naglich JG","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_296_2","first-page":"4001","article-title":"Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)\u20102, but not TIMP\u20101, inhibit shedding of tumor necrosis factor receptors in a human colon adenocarcinoma (Colo 205) cell line","volume":"58","author":"Lombard M","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_1_297_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1183-02"},{"key":"e_1_2_1_298_2","first-page":"98a","article-title":"A phase I trial of BMS\u2010275291: A novel non\u2010hydrozamate, sheddase\u2010sparing matrix metalloproteinase inhibitor with no dose\u2010limiting arthritis","volume":"20","author":"Hurwitz H","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_299_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2074"},{"key":"e_1_2_1_300_2","first-page":"500","article-title":"BMS\u2010275291. Bristol\u2010Myers Squibb","volume":"3","author":"Poulaki V","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_1_301_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.05.009"},{"key":"e_1_2_1_302_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.044"},{"key":"e_1_2_1_303_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0968"},{"key":"e_1_2_1_304_2","first-page":"83A","article-title":"CGS27023a, a potent and orally active matrix metalloprotease inhibitor with anti\u2010tumour activity","volume":"39","author":"Wood J","year":"1998","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_305_2","first-page":"411","article-title":"Anti\u2010tumor angiogenic effect of a matrix metalloproteinase inhibitor MMI270","volume":"23","author":"Nakamura ES","year":"2003","journal-title":"Anticancer Res"},{"key":"e_1_2_1_306_2","first-page":"1912","article-title":"Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer","volume":"7","author":"Levitt NC","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_307_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0856-4"},{"key":"e_1_2_1_308_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600446"},{"key":"e_1_2_1_309_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600310"},{"key":"e_1_2_1_310_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1383"},{"key":"e_1_2_1_311_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-004-0020-7"},{"key":"e_1_2_1_312_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07690.x"},{"key":"e_1_2_1_313_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07760.x"},{"key":"e_1_2_1_314_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006588708131"},{"key":"e_1_2_1_315_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013373516"},{"key":"e_1_2_1_316_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10168"},{"key":"e_1_2_1_317_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.584"},{"key":"e_1_2_1_318_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.153"},{"key":"e_1_2_1_319_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0804"},{"key":"e_1_2_1_320_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026504500555"},{"key":"e_1_2_1_321_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200302000-00001"},{"key":"e_1_2_1_322_2","first-page":"795","article-title":"The antiangiogenic agent Neovastat (AE\u2010941) induces endothelial cell apoptosis","volume":"1","author":"Boivin D","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_1_323_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014546909573"},{"key":"e_1_2_1_324_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf195"},{"key":"e_1_2_1_325_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2003.n.003"},{"key":"e_1_2_1_326_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90035-1"},{"key":"e_1_2_1_327_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.12.8.1403"},{"key":"e_1_2_1_328_2","first-page":"668","article-title":"AE\u2010941 (AEterna)","volume":"5","author":"Dredge K","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_1_329_2","first-page":"211","article-title":"Phase III trial of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy","volume":"22","author":"Escudier B","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_330_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.7144"},{"key":"e_1_2_1_331_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124702"},{"key":"e_1_2_1_332_2","first-page":"305","article-title":"Inhibition of angiogenic differentiation of human umbilical endothelial cells by curcumin","volume":"9","author":"Thaloor D","year":"1998","journal-title":"Cell Growth Differ"},{"key":"e_1_2_1_333_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207309200"},{"key":"e_1_2_1_334_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0292com"},{"key":"e_1_2_1_335_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0427fje"},{"key":"e_1_2_1_336_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90007-8"},{"key":"e_1_2_1_337_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118227"},{"key":"e_1_2_1_338_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-623"},{"key":"e_1_2_1_339_2","doi-asserted-by":"publisher","DOI":"10.1089\/108497801300189218"},{"key":"e_1_2_1_340_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.7507"},{"key":"e_1_2_1_341_2","first-page":"199","article-title":"Vitaxin applied molecular evolution","volume":"1","author":"Mikecz K","year":"2000","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_1_342_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1347::AID-CNCR1456>3.0.CO;2-0"},{"key":"e_1_2_1_343_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.suppl_2.ii96"},{"key":"e_1_2_1_344_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000901)87:5<716::AID-IJC14>3.0.CO;2-R"},{"key":"e_1_2_1_345_2","first-page":"4263","article-title":"Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts","volume":"62","author":"Burke PA","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_346_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja9603721"},{"key":"e_1_2_1_347_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm970832g"},{"key":"e_1_2_1_348_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi002101f"},{"key":"e_1_2_1_349_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00057-1"},{"key":"e_1_2_1_350_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2003.08.003"},{"key":"e_1_2_1_351_2","first-page":"959","article-title":"Novel small molecule alpha v integrin antagonists: Comparative anti\u2010cancer efficacy with known angiogenesis inhibitors","volume":"19","author":"Kerr JS","year":"1999","journal-title":"Anticancer Res"},{"key":"e_1_2_1_352_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm990049j"},{"key":"e_1_2_1_353_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(00)01545-2"},{"key":"e_1_2_1_354_2","first-page":"1189","article-title":"Effects of the novel alphav integrin antagonist SM256 and cis\u2010platinum on growth of murine squamous cell carcinoma PAM LY8","volume":"16","author":"Van Waes C","year":"2000","journal-title":"Int J Oncol"},{"key":"e_1_2_1_355_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00181-1"},{"key":"e_1_2_1_356_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0902-918"},{"key":"e_1_2_1_357_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90122-X"},{"key":"e_1_2_1_358_2","first-page":"183","article-title":"Further observation with thalidomide in lepra reactions","volume":"36","author":"Sheskin J","year":"1965","journal-title":"Lepr Rev"},{"key":"e_1_2_1_359_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_1_360_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(95)00050-X"},{"key":"e_1_2_1_361_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3679"},{"key":"e_1_2_1_362_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_1_363_2","first-page":"1","article-title":"Efficacy of low dose thalidomide in multiple myeloma","volume":"1","author":"Durie BG","year":"2000","journal-title":"Elec J Oncol"},{"key":"e_1_2_1_364_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"e_1_2_1_365_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.708"},{"key":"e_1_2_1_366_2","article-title":"Phase I trial of thalidomide in AIDS\u2010related Kaposi sarcoma","volume":"18","author":"Politi P","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_1_367_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2593"},{"key":"e_1_2_1_368_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2004.08.013"},{"key":"e_1_2_1_369_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90157-5"},{"key":"e_1_2_1_370_2","first-page":"1888","article-title":"A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen\u2010independent prostate cancer","volume":"7","author":"Figg WD","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_371_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_2_1_372_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000042321.94839.78"},{"key":"e_1_2_1_373_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200412000-00014"},{"key":"e_1_2_1_374_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1004"},{"key":"e_1_2_1_375_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf213"},{"key":"e_1_2_1_376_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.302"},{"key":"e_1_2_1_377_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2710"},{"key":"e_1_2_1_378_2","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/jco.2005.23.16_suppl.1500","article-title":"RTOG 0118: A phase III study of conventional radiation therapy alone vs. conventional radiation therapy plus thalidomide for multiple brain metastases","volume":"23","author":"Knisely JPS","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_379_2","first-page":"153","article-title":"The role of calcium in the regulation of invasion and angiogenesis","volume":"10","author":"Alessandro R","year":"1996","journal-title":"In Vivo"},{"key":"e_1_2_1_380_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.8705"},{"key":"e_1_2_1_381_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)35258-9","article-title":"Carboxyamido\u2010triazole inhibits angiogenesis by blocking the calcium\u2010mediated nitric\u2010oxide synthase\u2010vascular endothelial growth factor pathway","volume":"292","author":"Bauer KS","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_382_2","first-page":"1248","article-title":"Carboxyamido\u2010triazole induces apoptosis in bovine aortic endothelial and human glioma cells","volume":"6","author":"Ge S","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_383_2","doi-asserted-by":"crossref","first-page":"21505","DOI":"10.1016\/S0021-9258(17)31833-1","article-title":"Calcium influx modulates expression of matrix metalloproteinase\u20102 (72 kDa type IV collagenase, gelatinase A) expression","volume":"269","author":"Kohn EC","year":"1994","journal-title":"J Biol Chem"},{"key":"e_1_2_1_384_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.5.1307"},{"key":"e_1_2_1_385_2","first-page":"569","article-title":"Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers","volume":"56","author":"Kohn EC","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_1_386_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1985"},{"key":"e_1_2_1_387_2","first-page":"1600","article-title":"A phase I trial of carboxyamido\u2010triazole and paclitaxel for relapsed solid tumors: Potential efficacy of the combination and demonstration of pharmacokinetic interaction","volume":"7","author":"Kohn EC","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_388_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.781"},{"key":"e_1_2_1_389_2","first-page":"2324","article-title":"A pharmacokinetically guided phase II study of carboxyamido\u2010triazole in androgen\u2010independent prostate cancer","volume":"5","author":"Bauer KS","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_390_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.52.426"},{"key":"e_1_2_1_391_2","first-page":"43","article-title":"The novel isocoumarin 2\u2010(8\u2010hydroxy\u20106\u2010methoxy\u20101\u2010oxo\u20101H\u20102\u2010benzopyran\u20103\u2010yl) propionic acid (NM\u20103) induces lethality of human carcinoma cells by generation of reactive oxygen species","volume":"1","author":"Yin L","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_1_392_2","first-page":"789","article-title":"Antineoplastic effects of chemotherapeutic agents are potentiated by NM\u20103, an inhibitor of angiogenesis","volume":"62","author":"Reimer CL","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_1_393_2","first-page":"6958","article-title":"NM\u20103, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity","volume":"60","author":"Salloum RM","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_394_2","first-page":"39","article-title":"Vascular endothelial growth factor receptor\u20102\u2010blocking antibody potentiates radiation\u2010induced long\u2010term control of human tumor xenografts","volume":"61","author":"Kozin SV","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_1_395_2","first-page":"1076","article-title":"Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial cells","volume":"36","author":"Sakamoto T","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_1_396_2","first-page":"6727","article-title":"Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without a steroid","volume":"49","author":"Tanaka NG","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_1_397_2","first-page":"161","article-title":"The bacterial polysaccharide tecogalan blocks growth of breast cancer cells in vivo","volume":"8","author":"Yunmbam MK","year":"2001","journal-title":"Oncol Rep"},{"key":"e_1_2_1_398_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055624"},{"key":"e_1_2_1_399_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010638"},{"key":"e_1_2_1_400_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1195"},{"key":"e_1_2_1_401_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90298-2"},{"key":"e_1_2_1_402_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2001.22815"},{"key":"e_1_2_1_403_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00121-9"},{"key":"e_1_2_1_404_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00112-8"},{"key":"e_1_2_1_405_2","first-page":"32","article-title":"Recent progress in the clinical development of docetaxel (Taxotere)","volume":"26","author":"Hortobagyi GN","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_1_406_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800000241"},{"key":"e_1_2_1_407_2","first-page":"12","article-title":"Combination of taxanes with radiation: Preclinical studies","volume":"9","author":"Milas L","year":"1999","journal-title":"Semin Radiat Oncol"},{"key":"e_1_2_1_408_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00360-4"},{"key":"e_1_2_1_409_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199905000-00008"},{"key":"e_1_2_1_410_2","first-page":"4191","article-title":"Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo","volume":"5","author":"Mason KA","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_411_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10907"},{"key":"e_1_2_1_412_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.3.505"},{"key":"e_1_2_1_413_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0195-27"},{"key":"e_1_2_1_414_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00323-5"},{"key":"e_1_2_1_415_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(03)00002-9"},{"key":"e_1_2_1_416_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd819"},{"key":"e_1_2_1_417_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601035"},{"key":"e_1_2_1_418_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00336-2"},{"key":"e_1_2_1_419_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63273-7"},{"key":"e_1_2_1_420_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3986"},{"key":"e_1_2_1_421_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0074"},{"key":"e_1_2_1_422_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"key":"e_1_2_1_423_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.10.011"},{"key":"e_1_2_1_424_2","first-page":"1144","article-title":"The First International Conference on Vascular Targeting: Meeting overview","volume":"63","author":"Thorpe PE","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_1_425_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0300rev"}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmed.20059","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.20059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:48:18Z","timestamp":1736365698000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.20059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":424,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1002\/med.20059"],"URL":"https:\/\/doi.org\/10.1002\/med.20059","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}